AstraZeneca's Portfolio and Pipeline Support Solid Long-Term Growth
AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets ...
MedPage Today1d
NCI Flags 'Cancer Moonshot'; Dr. Hologram Will See You; Fraud Crackdown Continues
The American Cancer Society awarded its 2025 Medal of Honor to W. Kimryn Rathmell, MD, PhD, renowned kidney cancer expert and ...
AstraZeneca PLC (NASDAQ:AZN) Given Average Rating of “Buy” by Analysts
AstraZeneca PLC (NASDAQ:AZN – Get Free Report) has been given an average recommendation of “Buy” by the ten ratings firms that are currently covering the company, Marketbeat.com reports. One equities ...
Stocks to watch: Tata Power, HCL Tech, NMDC, Shilpa Medicare among shares to remain in focus today
Following approval from the Republic of the Philippines Securities and Exchange Commission, the company's step-down ...
Ionis and AstraZeneca’s WAINZUA gets EU approval for ATTRv-PN treatment
Ionis Pharmaceuticals (IONS) announced that Ionis and AstraZeneca’s (AZN) WAINZUA eplontersen has been approved in the European Union EU for ...
UBS Keeps Their Buy Rating on AstraZeneca (AZN)
UBS analyst Matthew Weston maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £142.00. The ...
AstraZeneca reports positive outcomes from trial of Imfinzi
AstraZeneca has reported positive “high-level” outcomes from the randomised Phase III MATTERHORN trial of Imfinzi (durvalumab ...